FNBP4 is a Potential Biomarker Associated with Cuproptosis and Promotes Tumor Progression in Hepatocellular Carcinoma

References

• Zhang Y, Zhang S, Liu J, et al. Identification of serum glycobiomarkers for Hepatocellular Carcinoma using lectin microarrays. Front Immunol. 2022;13:973993. doi:10.3389/fimmu.2022.973993
   PubMed Web of Science ®Google Scholar
• Luna-Marco C, Ubink A, Kopsida M, Heindryckx F. Endoplasmic Reticulum Stress and Metabolism in Hepatocellular Carcinoma. Am J Pathol. 2022. doi:10.1016/j.ajpath.2022.09.012
   PubMed Web of Science ®Google Scholar
• Cho K, Ro SW, Seo SH, et al. Genetically Engineered Mouse Models for Liver Cancer. Cancers. 2019;12(1):14. doi:10.3390/cancers12010014
   PubMed Web of Science ®Google Scholar
• Llovet JM, Castet F, Heikenwalder M, et al. Immunotherapies for hepatocellular carcinoma. Nat Rev Clin Oncol. 2022;19(3):151–172. doi:10.1038/s41571-021-00573-2
   PubMed Web of Science ®Google Scholar
• Di Federico A, Rizzo A, Carloni R, et al. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials. Expert Opin Investig Drugs. 2022;31(4):361–369. doi:10.1080/13543784.2022.2009455
   PubMed Web of Science ®Google Scholar
• Viscardi G, Tralongo AC, Massari F, et al. Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis. Eur J Cancer. 2022;177:175–185. doi:10.1016/j.ejca.2022.09.031
   PubMed Web of Science ®Google Scholar
• Li D, Toh HC, Merle P, et al. Atezolizumab plus Bevacizumab versus Sorafenib for Unresectable Hepatocellular Carcinoma: results from Older Adults Enrolled in the IMbrave150 Randomized Clinical Trial. Liver Cancer. 2022;11(6):558–571. doi:10.1159/000525671
   PubMed Web of Science ®Google Scholar
• Rizzo A, Ricci AD, Di Federico A, et al. Predictive Biomarkers for Checkpoint Inhibitor-Based Immunotherapy in Hepatocellular Carcinoma: where Do We Stand? Front Oncol. 2021;11:803133. doi:10.3389/fonc.2021.803133
   PubMed Web of Science ®Google Scholar
• Li J, Xie J, Wu D, et al. A pan-cancer analysis revealed the role of the SLC16 family in cancer. Channels. 2021;15(1):528–540. doi:10.1080/19336950.2021.1965422
   PubMed Web of Science ®Google Scholar
• Cammarota A, Zanuso V, Manfredi GF, Murphy R, Pinato DJ, Rimassa L. Immunotherapy in hepatocellular carcinoma: how will it reshape treatment sequencing? Ther Adv Med Oncol. 2023;15:17588359221148029. doi:10.1177/17588359221148029
   Web of Science ®Google Scholar
• Rizzo A, Nannini M, Novelli M, Dalia Ricci A, Scioscio VD, Pantaleo MA. Dose reduction and discontinuation of standard-dose regorafenib associated with adverse drug events in cancer patients: a systematic review and meta-analysis. Ther Adv Med Oncol. 2020;12:1758835920936932. doi:10.1177/1758835920936932
   Web of Science ®Google Scholar
• Faix J, Grosse R. Staying in shape with formins. Dev Cell. 2006;10(6):693–706. doi:10.1016/j.devcel.2006.05.001
   PubMed Web of Science ®Google Scholar
• Ahangar P, Cowin AJ. Reforming the Barrier: the Role of Formins in Wound Repair. Cells. 2022;11(18):2779. doi:10.3390/cells11182779
   PubMed Web of Science ®Google Scholar
• Chiereghin C, Robusto M, Massa V, et al. Role of Cytoskeletal Diaphanous-Related Formins in Hearing Loss. Cells. 2022;11(11):1726. doi:10.3390/cells11111726
   PubMed Web of Science ®Google Scholar
• Young KG, Copeland JW. Formins in cell signaling. Biochim Biophys Acta. 2010;1803(2):183–190. doi:10.1016/j.bbamcr.2008.09.017
   PubMed Web of Science ®Google Scholar
• Yoon BK, Hwang N, Chun KH, et al. Sp1-Induced FNBP1 Drives Rigorous 3D Cell Motility in EMT-Type Gastric Cancer Cells. Int J Mol Sci. 2021;22(13):6784. doi:10.3390/ijms22136784
   PubMed Web of Science ®Google Scholar
• Suman P, Mishra S, Chander H. High expression of FBP17 in invasive breast cancer cells promotes invadopodia formation. Med Oncol. 2018;35(5):71. doi:10.1007/s12032-018-1132-5
   PubMed Web of Science ®Google Scholar
• Depraetere V, Golstein P. WW domain-containing FBP-30 is regulated by p53. Cell Death Differ. 1999;6(9):883–889. doi:10.1038/sj.cdd.4400564
   PubMed Web of Science ®Google Scholar
• Song S, Zhang M, Xie P, Wang S, Wang Y. Comprehensive analysis of cuproptosis-related genes and tumor microenvironment infiltration characterization in breast cancer. Front Immunol. 2022;13:978909. doi:10.3389/fimmu.2022.978909
   PubMed Web of Science ®Google Scholar
• Feng W, Su S, Song C, et al. Effects of Copper Exposure on Oxidative Stress, Apoptosis, Endoplasmic Reticulum Stress, Autophagy and Immune Response in Different Tissues of Chinese Mitten Crab (Eriocheir sinensis). Antioxidants. 2022;11(10). doi:10.3390/antiox11102029
   Web of Science ®Google Scholar
• Siddiqui MA, Alhadlaq HA, Ahmad J, Al-Khedhairy AA, Musarrat J, Ahamed M. Copper oxide nanoparticles induced mitochondria mediated apoptosis in human hepatocarcinoma cells. PLoS One. 2013;8(8):e69534. doi:10.1371/journal.pone.0069534
   PubMed Web of Science ®Google Scholar
• Kuo HW, Chen SF, Wu CC, Chen DR, Lee JH. Serum and tissue trace elements in patients with breast cancer in Taiwan. Biol Trace Elem Res. 2002;89(1):1–11. doi:10.1385/bter:89:1:1
   PubMed Web of Science ®Google Scholar
• Zhang X, Yang Q. Association between serum copper levels and lung cancer risk: a meta-analysis. J Int Med Res. 2018;46(12):4863–4873. doi:10.1177/0300060518798507
   PubMed Web of Science ®Google Scholar
• Moffett JR, Puthillathu N, Vengilote R, Jaworski DM, Namboodiri AM. Acetate Revisited: a Key Biomolecule at the Nexus of Metabolism, Epigenetics and Oncogenesis-Part 1: acetyl-CoA, Acetogenesis and Acyl-CoA Short-Chain Synthetases. Front Physiol. 2020;11:580167. doi:10.3389/fphys.2020.580167
   PubMed Web of Science ®Google Scholar
• Koizumi M, Fujii J, Suzuki K, et al. A marked increase in free copper levels in the plasma and liver of LEC rats: an animal model for Wilson disease and liver cancer. Free Radic Res. 1998;28(5):441–450. doi:10.3109/10715769809066881
   PubMed Web of Science ®Google Scholar
• Tsvetkov P, Coy S, Petrova B, et al. Copper induces cell death by targeting lipoylated TCA cycle proteins. Science. 2022;375(6586):1254–1261. doi:10.1126/science.abf0529
   PubMed Web of Science ®Google Scholar
• Zhang Z, Zeng X, Wu Y, Liu Y, Zhang X, Song Z. Cuproptosis-Related Risk Score Predicts Prognosis and Characterizes the Tumor Microenvironment in Hepatocellular Carcinoma. Front Immunol. 2022;13:925618. doi:10.3389/fimmu.2022.925618
   PubMed Web of Science ®Google Scholar
• Peng X, Zhu J, Liu S, et al. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma. Front Immunol. 2022;13:990790. doi:10.3389/fimmu.2022.990790
   PubMed Web of Science ®Google Scholar
• Wang G, Xiao R, Zhao S, et al. Cuproptosis regulator-mediated patterns associated with immune infiltration features and construction of cuproptosis-related signatures to guide immunotherapy. Front Immunol. 2022;13:945516. doi:10.3389/fimmu.2022.945516
   PubMed Web of Science ®Google Scholar
• Chen D, Cui QC, Yang H, Dou QP. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006;66(21):10425–10433. doi:10.1158/0008-5472.Can-06-2126
   PubMed Web of Science ®Google Scholar
• O’Day SJ, Eggermont AM, Chiarion-Sileni V, et al. Final results of Phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. J Clin Oncol. 2013;31(9):1211–1218. doi:10.1200/jco.2012.44.5585
   PubMed Web of Science ®Google Scholar
• Chen L, Min J, Wang F. Copper homeostasis and cuproptosis in health and disease. Signal Transduct Target Ther. 2022;7(1):378. doi:10.1038/s41392-022-01229-y
   PubMed Web of Science ®Google Scholar
• Yang JC, Hu JJ, Li YX, Luo W, Liu JZ, Ye DW. Clinical Applications of Liquid Biopsy in Hepatocellular Carcinoma. Front Oncol. 2022;12:781820. doi:10.3389/fonc.2022.781820
   PubMedGoogle Scholar
• Feng H, Zhuo Y, Zhang X, et al. Tumor Microenvironment in Hepatocellular Carcinoma: key Players for Immunotherapy. J Hepatocell Carcinoma. 2022;9:1109–1125. doi:10.2147/jhc.S381764
   PubMed Web of Science ®Google Scholar
• Dash S, Aydin Y, Wu T. Integrated stress response in hepatitis C promotes Nrf2-related chaperone-mediated autophagy: a novel mechanism for host-microbe survival and HCC development in liver cirrhosis. Semin Cell Dev Biol. 2020;101:20–35. doi:10.1016/j.semcdb.2019.07.015
   PubMed Web of Science ®Google Scholar
• Shokouhian B, Aboulkheyr EH, Negahdari B, et al. Hepatogenesis and hepatocarcinogenesis: alignment of the main signaling pathways. J Cell Physiol. 2022;237(11):3984–4000. doi:10.1002/jcp.30862
   PubMed Web of Science ®Google Scholar
• Xie J, Zhu Z, Cao Y, Ruan S, Wang M, Shi J. Solute carrier transporter superfamily member SLC16A1 is a potential prognostic biomarker and associated with immune infiltration in skin cutaneous melanoma. Channels. 2021;15(1):483–495. doi:10.1080/19336950.2021.1953322
   PubMed Web of Science ®Google Scholar
• Xie J, Ruan S, Zhu Z, et al. Database mining analysis revealed the role of the putative H(+)/sugar transporter solute carrier family 45 in skin cutaneous melanoma. Channels. 2021;15(1):496–506. doi:10.1080/19336950.2021.1956226
   PubMed Web of Science ®Google Scholar
• Qie S, Yoshida A, Parnham S, et al. Targeting glutamine-addiction and overcoming CDK4/6 inhibitor resistance in human esophageal squamous cell carcinoma. Nat Commun. 2019;10(1):1296. doi:10.1038/s41467-019-09179-w
   PubMed Web of Science ®Google Scholar
• Tchakarska G, Sola B. The double dealing of cyclin D1. Cell Cycle. 2020;19(2):163–178. doi:10.1080/15384101.2019.1706903
   PubMed Web of Science ®Google Scholar
• Montalto FI, De Amicis F. Cyclin D1 in Cancer: a Molecular Connection for Cell Cycle Control, Adhesion and Invasion in Tumor and Stroma. Cells. 2020;9:12. doi:10.3390/cells9122648
   Web of Science ®Google Scholar
• Qie S, Diehl JA. Cyclin D1, cancer progression, and opportunities in cancer treatment. J Mol Med. 2016;94(12):1313–1326. doi:10.1007/s00109-016-1475-3
   PubMed Web of Science ®Google Scholar
• Yu FX, Zhao B, Guan KL. Hippo Pathway in Organ Size Control, Tissue Homeostasis, and Cancer. Cell. 2015;163(4):811–828. doi:10.1016/j.cell.2015.10.044
   PubMed Web of Science ®Google Scholar
• Chen D, Sun Y, Wei Y, et al. LIFR is a breast cancer metastasis suppressor upstream of the Hippo-YAP pathway and a prognostic marker. Nat Med. 2012;18(10):1511–1517. doi:10.1038/nm.2940
   PubMed Web of Science ®Google Scholar
• Hao Y, Chun A, Cheung K, Rashidi B, Yang X. Tumor suppressor LATS1 is a negative regulator of oncogene YAP. J Biol Chem. 2008;283(9):5496–5509. doi:10.1074/jbc.M709037200
   PubMed Web of Science ®Google Scholar
• Lamar JM, Stern P, Liu H, Schindler JW, Jiang ZG, Hynes RO. The Hippo pathway target, YAP, promotes metastasis through its TEAD-interaction domain. Proc Natl Acad Sci U S A. 2012;109(37):E2441–2450. doi:10.1073/pnas.1212021109
   PubMed Web of Science ®Google Scholar
• Kim NG, Koh E, Chen X, Gumbiner BM. E-cadherin mediates contact inhibition of proliferation through Hippo signaling-pathway components. Proc Natl Acad Sci U S A. 2011;108(29):11930–11935. doi:10.1073/pnas.1103345108
   PubMed Web of Science ®Google Scholar
• Duan WJ, He RR. Cuproptosis: copper-induced regulated cell death. Sci China Life Sci. 2022;65(8):1680–1682. doi:10.1007/s11427-022-2106-6
   PubMed Web of Science ®Google Scholar
• Kodama H, Fujisawa C, Bhadhprasit W. Inherited copper transport disorders: biochemical mechanisms, diagnosis, and treatment. Curr Drug Metab. 2012;13(3):237–250. doi:10.2174/138920012799320455
   PubMed Web of Science ®Google Scholar
• Poznański J, Sołdacki D, Czarkowska-Pączek B, et al. Cirrhotic Liver of Liver Transplant Recipients Accumulate Silver and Co-Accumulate Copper. Int J Mol Sci. 2021;22(4):1782. doi:10.3390/ijms22041782
   PubMed Web of Science ®Google Scholar
• Mayr JA, Feichtinger RG, Tort F, Ribes A, Sperl W. Lipoic acid biosynthesis defects. J Inherit Metab Dis. 2014;37(4):553–563. doi:10.1007/s10545-014-9705-8
   PubMed Web of Science ®Google Scholar
• Yan C, Niu Y, Ma L, Tian L, Ma J. System analysis based on the cuproptosis-related genes identifies LIPT1 as a novel therapy target for liver hepatocellular carcinoma. J Transl Med. 2022;20(1):452. doi:10.1186/s12967-022-03630-1
   PubMed Web of Science ®Google Scholar
• Bai WD, Liu JY, Li M, et al. A Novel Cuproptosis-Related Signature Identified DLAT as a Prognostic Biomarker for Hepatocellular Carcinoma Patients. World J Oncol. 2022;13(5):299–310. doi:10.14740/wjon1529
   PubMedGoogle Scholar
• Chen Z, Guo Y, Zhao D, et al. Comprehensive Analysis Revealed that CDKN2A is a Biomarker for Immune Infiltrates in Multiple Cancers. Front Cell Dev Biol. 2021;9:808208. doi:10.3389/fcell.2021.808208
   PubMed Web of Science ®Google Scholar
• Zhou Y, Wang XB, Qiu XP, Shuai Z, Wang C, Zheng F. CDKN2A promoter methylation and hepatocellular carcinoma risk: a meta-analysis. Clin Res Hepatol Gastroenterol. 2018;42(6):529–541. doi:10.1016/j.clinre.2017.07.003
   PubMed Web of Science ®Google Scholar